Table 4 |
|||
|
Doses of rituximab stratified by response in patients with different autoimmune diseases |
|||
|
Mean (SD) dose, mg |
|||
|
|
|||
|
Diagnosis |
No response |
Partial response |
Complete response |
|
|
|||
|
Total |
n = 39 1,990 (798) |
n = 132 2,683 (1,408) |
n = 122 2,528 (1,346) |
|
Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis |
n = 1 2,000 (-) |
n = 4 2,500 (1,000) |
- |
|
Autoimmune haemolytic anaemia |
n = 1 2,320 (-) |
n = 1 2,000 (-) |
n = 1 2,380 (-) |
|
Autoimmune thrombocytopenia |
- |
n = 5 2,248 (1,321) |
n = 5 2,956 (641) |
|
Glomerulonephritis |
- |
n = 6 1,625 (826) |
n = 2 4,100 (2,970) |
|
Cryoglobulinaemic vasculitis |
- |
n = 3 2,960 (1,154) |
n = 1 2,000 (-) |
|
Wegener's granulomatosis/microscopic polyangiitis |
n = 4 2,193 (561) |
n = 29 3,474 (1,642) |
n = 22 2,586 (1,384) |
|
Multiple sclerosis/neuromyelitis optica |
n = 9 2,022 (570) |
n = 31 2,678 (903) |
n = 14 3,157 (1,992) |
|
Myasthenia gravis |
- |
n = 2 2,500 (707) |
n = 2 1,225 (1,662) |
|
Pemphigus |
n = 2 1,500 (707) |
n = 13 1,770 (899) |
n = 22 1,769 (1,352) |
|
Sjögren's syndrome |
- |
n = 2 2,312 (441) |
n = 2 3,000 (1,414) |
|
Polydermatomyositis |
n = 5 1,700 (447) |
n = 6 3,900 (3,209) |
n = 10 2,818 (1,003) |
|
Systemic lupus erythematosus |
n = 15 2,121 (1,099) |
n = 27 2,440 (1,119) |
n = 37 2,499 (926) |
|
Vasculitis |
n = 2 1,500 (707) |
n = 3 2,200 (346) |
n = 4 3,000 (1,155) |
|
|
|||
|
RA, rheumatoid arthritis; SD, standard deviation. |
|||
|
Tony et al. Arthritis Research & Therapy 2011 13:R75 doi:10.1186/ar3337 |
|||
